Weight Loss Drugs: A Game Changer in the Fight Against Obesity - New InsightAce Analytic Report Investigates
Structure Therapeutics Inc. (GPCR)
Company Research
Source: PR Newswire
JERSEY CITY, N.J., June 21, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Weight Loss Drugs Market- (By Drug Type (Prescription and Over-the-counter), By Product (Wegovy, Ozempic, Saxenda, Zepbound, Mounjaro and Others)), By Distribution Channel, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."According to the latest research by InsightAce Analytic, the Global Weight Loss Drugs Market is valued at US$ 26.3 Bn in 2023, and it is expected to reach US$ 108.9 Bn by 2031, with a CAGR of 19.7% during the forecast period of 2024-2031.Download Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2526 Weight loss drugs work through various mechanisms in the body to promote weight loss, such as reducing appetite, increasing feelings of fullness, decreasing absorption of nutrients, or increasing calorie expenditure.The weight loss drugs market is propelled by the escalat
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.MarketBeat
- Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $118.00 price target on the stock.MarketBeat
- Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development OfficerGlobeNewswire
- Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.MarketBeat
- Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.MarketBeat
GPCR
Sec Filings
- 9/20/24 - Form 4
- 9/20/24 - Form 3
- 9/20/24 - Form 4
- GPCR's page on the SEC website